



US007070959B1

(12) **United States Patent**
Papadopoulos et al.

(10) **Patent No.:** **US 7,070,959 B1**
(45) **Date of Patent:** ***Jul. 4, 2006**

(54) **MODIFIED CHIMERIC POLYPEPTIDES
WITH IMPROVED PHARMACOKINETIC
PROPERTIES**

FOREIGN PATENT DOCUMENTS

WO	WO97/44453	11/1997
WO	WO98/13071	4/1998
WO	WO99/03996	1/1999

(75) Inventors: **Nicholas J. Papadopoulos**,
Lagrangeville, NY (US); **Samuel Davis**,
New York, NY (US); **George D.**
Yancopoulos, Yorktown Heights, NY
(US)

OTHER PUBLICATIONS

Herley et al. (1999), *Biochem. Biophys. Res. Comm.* 262:
731-738.*

Terman, B. I., et al, "Identification of a new endothelial cell
growth factor receptor tyrosine kinase", *Oncogene* (1991)
6:1677-1683.

Terman, B.I., et al, "Identification of the KDR tyrosine
kinase as a receptor for vascular endothelial cell growth
factor", *Biochem Biophys Res Comm* (1992) 187(3):1579-
1586.

Tsutsumi, Y., et al, "PEGylation of interleukin-6 effectively
increases its thrombopoietic potency", *Thrombosis and
Haemostasis* (1997) 77(1):168-173.

Dunca, R. and Spreafico, F., "Polymer Conjugates", *Drug
Delivery Systems* (1994) 27(4):290-306.

Hileman, R.E., et al., "Glycosaminoglycan-protein interac-
tions: definitions of consensus sites in glycosaminoglycan
binding proteins", *BioEssays* (1998) 20:156-167.

deVries, Carlie, et al., "The *fms*-like tyrosine kinase, a
receptor for vascular endothelial growth factor", *Science*
(1992) 225:989-991.

Sharifi, J., et al., "Improving monoclonal antibody
pharmacokinetics via chemical modification", *Quart J Nucl
Med* (1998) 42:242-249.

Jensen-Pippo, K.E., et al., "Enteral bioavailability of human
granulocyte colony stimulating factor conjugated with poly-
(ethylene glycol)", (1996) *Pharm Res* 13(1):102-107.

Tanaka, K., et al., "Characterization of the extracellular
domain in vascular endothelial growth factor receptor-1
(Flt-1 Tyrosine kinase)", (1997) *Jpn J Cancer Res* 88:767-
876.

Yang, J.C., et al., "The use of polyethylene glycol-modified
interleukin-2 (PEG-IL-2) in the treatment of patients with
metastatic renal cell carcinoma and melanoma", (1995) *Cancer*
76(4): 687-694.

(Continued)

Primary Examiner—Lorraine Spector

Assistant Examiner—Jon M Lockard

(74) *Attorney, Agent, or Firm*—Valeta Gregg, Esq.

(73) Assignee: **Regeneron Pharmaceuticals, Inc.**,
Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **10/009,852**

(22) PCT Filed: **May 23, 2000**

(86) PCT No.: **PCT/US00/14142**

§ 371 (c)(1),
(2), (4) Date: **Dec. 6, 2001**

(87) PCT Pub. No.: **WO00/75319**

PCT Pub. Date: **Dec. 14, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/138,133, filed on Jun.
8, 1999.

(51) **Int. Cl.**
C12N 15/62 (2006.01)
C12N 15/63 (2006.01)
C07H 21/04 (2006.01)
C07K 16/00 (2006.01)
C07K 14/00 (2006.01)

(52) **U.S. Cl.** **435/69.7**; 435/70.1; 435/71.1;
435/320.1; 435/325; 435/252.3; 530/387.3;
530/350; 536/23.4

(58) **Field of Classification Search** 435/69.7,
435/320.1, 70.1, 71.1; 530/387.3
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,712,380	A	1/1998	Kendall et al.
6,011,003	A	1/2000	Charnock-Jones et al.
6,100,071	A *	8/2000	Davis-Smyth et al. 435/69.7

15 Claims, 55 Drawing Sheets

OTHER PUBLICATIONS

Davis-Smyth, T., et al., 1996, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction-cascade", *The EMBO Journal* 15(18):4919-4927.

Holash, J., et al. (2002) *PNAS*, vol. 99, No. 17, pp. 11393-11398.

Heidaran, M.A., (1990) *The Journal of Biological Chemistry*, vol. 265, No. 31, Issue of Nov. 5, pp. 18741-18744.

Cunningham, S.A. et al., (1997) *Biochemical and Biophysical Research Communications*, vol. 231, pp. 596-599.

Fuh, G. et al. (1998) *The Journal of Biological Chemistry*, vol. 273, No. 18, Issue of May 1, pp. 11197-11204.

Wiesmann, C. et al. (1997) *Cell*, vol. 91, pp. 695-704.

Barleon, B. et al. (1997) *The Journal of Biological Chemistry*, vol. 272, No. 16, pp. 10382-10388.

Davis-Smyth, T. et al. (1998) *The Journal of Biological Chemistry*, vol. 273, No. 6, pp. 3216-3222.

* cited by examiner

Fig. 1.




Fig. 2.






Fig.3.





Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.